Ihnatko Ya. Ya., Derbak M. A., Chubirko K. I., Ihnatko O. I.

CLINICAL CHARACTERISTICS OF THE COURSE OF CORONARY HEART DISEASE WITH STABLE TENSION STENOCARDIA IN COMORBIDITY WITH NON-ALCOHOLIC STEATOHEPATITIS

---

Show/Download

About the author:

Ihnatko Ya. Ya., Derbak M. A., Chubirko K. I., Ihnatko O. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The diseases of the hepatobiliary system significantly aggravate the course of coronary heart disease, in particular, this applies to non-alcoholic steatohepatitis. Therefore, an important problem of current medicine is the study of common pathogenetic mechanisms of the development of this combined pathology. The aim of the work was to determine the features of the clinical course of coronary heart disease with stable tension angina in combination with non-alcoholic steatohepatitis depending on metabolic factors. 145 patients with coronary heart disease in combination with non-alcoholic steatohepatitis and 100 patients with coronary heart disesase without non-alcoholic steatohepatitis were examined. The clinical symptoms were characterized by the non-specificity of signs in relation to fatty liver damage. The clinical course of coronary heart disease in the presence of non-alcoholic steatohepatitis depends on the number of metabolic factors. In patients with coronary heart disease in combination with non-alcoholic steatohepatitis and metabolic risk factors, atrial fibrillation and the left or right branches of the bundle branch block are significantly more often registered than in patients with coronary heart disease without non-alcoholic steatohepatitis. The patients with coronary heart disease in the presence of non-alcoholic steatohepatitis and metabolic risk factors require hospitalization with a greater number of bed-days than patients with coronary heart disease without metabolic factors.

Tags:

Bibliography:

1. Bentsa TM. Nealkoholna zhyrova khvoroba pechinky ta sertsevo-sudynni zakhvoriuvannia: osoblyvosti komorbidnoho perebihu. 2020;1(237):44-7. [in Ukrainian].
2. Qiao Y-N, Zou Y-L, Guo S-D. Low-density lipoprotein particles in atherosclerosis. Front Physiol. 2022;13:1-15.
3. Parham JS, Goldberg AC. Review of recent clinical trials and their impact on the treatment of hypercholesterolemia. Prog Cardiovasc Dis. 2022;75:90-6.
4. Kounatidis D, Vallianou NG, Poulaki A, Evangelopoulos A, Panagopoulos F, Stratigou T, et al. ApoB100 and Atherosclerosis: What’s New in the 21st Century? Metabolites. 2024;14(2):123-7.
5. Scuruchi M, Poti F, Rodriguez-Carrio J, Campo GM, Mandraffino G. Biglycan and atherosclerosis: lessons from high cardiovascular risk conditions. Biochim Biophys Acta (BBA)-Molecular Cell Biol Lipids. 2020;1865(2):145-8.
6. Gugliucci A. Triglyceride-rich lipoprotein metabolism: key regulators of their flux. J Clin Med. 2023;12(13):43-9.
7. Heeren J, Scheja L. Metabolic-associated fatty liver disease and lipoprotein metabolism. Mol Metab. 2021;50:10-12.
8. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:10-22.
9. Martin A, Lang S, Goeser T, Demir M, Steffen H-M, Kasper P. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022;24(7):533-46.
10. Stepanov YuM, Filippova OIu. Evoliutsiia uiavlen pro nealkoholnu zhyrovu khvorobu pechinky: vid ryzyku do katastrofy. Zaporozhskyi medytsynskyi zhurnal. 2020;2:267-74. [in Ukrainian].
11. Vatseba B, Virstyuk N. Changes of Cholecystokinin-pancreozymine in Patients with Chronic Acalculous Cholecystitis in Combination with Non-alcoholic Fatty Disease and Stable Ischemic Heart Disease. World Sci. 2021;5:55-67.
12. Vakaliuk II, Virstiuk NH. Rol biolohichnykh markeriv steatozu ta prozapalnoi lanky v prohresuvanni nealkoholnoi zhyrovoi khvoroby pechinky v patsiientiv zi stabilnoiu ishemichnoiu khvoroboiu sertsia. Terapevtyka. 2021;2(1):27-32. [in Ukrainian].
13. Boiuka OV, Matiukha LE, Protsiuk OV. Patsiienty vysokoho sertsevo-sudynnoho ryzyku u praktytsi likaria pervynnoi lanky. Simeina Medytsyna Yevropeiski praktyky. 2022;3:56-62. [in Ukrainian].
14. Anokhina HA. Nealkoholna zhyrova khvoroba pechinky yak multysystemne metabolitne zakhvoriuvannia: osoblyvosti profilaktyky ta likuvannia. Praktykuiuchyi likar. 2018;7(3):35-40. [in Ukrainian].
15. MOZ Ukrainy. Nakaz MOZ Ukrainy № 826 vid 06.11.2014 r. Pro zatverdzhennia unifikovanoho klinichnoho protokolu pervynnoi, vtorynnoi (spetsializovanoi) medychnoi dopomohy «Nealkoholnyi steatohepatyt». Kyiv: MOZ Ukrainy. 2014. 40 s. [in Ukrainian].
16. Kasper P, Martin A, Lang S, Kuetting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clinical research in cardiology. 2021;110:921-937.
17. Dimala CA, Nso N, Wasserlauf J, Njei B. Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. Current Problems in Cardiology. 2024;49(7):1010-18.
18. Qiao ZP, Zheng KI, Zhu PW, Gao F, Ma HL, Li G, et al. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases. 2020;30(10):1820-1825.
19. Vakalyuk I, Virstyuk N,Vakaliuk I. Prognosis assessment of the combined course of stable coronary heart disease and non-alcoholic steatohepatitis in patients after revascularization interventions. Georgian Medical News. 2020;308:47-52.

Publication of the article:

«Bulletin of problems biology and medicine», 2024 Issue 2, 173, 230-235 pages, index UDC 616.12-005.4:616.12-009.72:616.36-003.826:577.112:577.17]-036

DOI:

10.29254/2077-4214-2024-2-173-230-235